{"DataElement":{"publicId":"6712214","version":"1","preferredName":"Cisplatin Prior Exposure Type","preferredDefinition":"The text response that indicates the prior exposure type a patient has had with regards to cisplatin.","longName":"CISPL_PR_EXP_TYP","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6712209","version":"1","preferredName":"Cisplatin Prior Exposure","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition._Earlier in time or order._The act of subjecting someone or something to an influencing experience.","longName":"2228639v1.0:3876243v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2228639","version":"1","preferredName":"Cisplatin","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","longName":"C376","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6EF4E2B-74FF-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-05-13","modifiedBy":"ONEDATA","dateModified":"2005-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3876243","version":"1","preferredName":"Prior Exposure","preferredDefinition":"Earlier in time or order.:Contact with infectious agents (bacteria or viruses) in a manner that promotes transmission and increases the likelihood of disease. (CDC)","longName":"C25629:C17941","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Exposure","conceptCode":"C17941","definition":"The act of subjecting someone or something to an influencing experience.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5A8347A-7F6B-747B-E040-BB89AD4312D0","latestVersionIndicator":"Yes","beginDate":"2013-09-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-09-05","modifiedBy":"ONEDATA","dateModified":"2013-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8735FE12-E395-248E-E053-F662850AEFBA","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-04-23","changeDescription":"Curated to support EC10183","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6712211","version":"1","preferredName":"Cisplatin Exposure Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6712211v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cisplatin Ineligible","valueDescription":"Cisplatin Ineligibility","ValueMeaning":{"publicId":"6712212","version":"1","preferredName":"Cisplatin Ineligibility","longName":"6712212","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: The state or quality of being disqualified by law, rule, or provision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ineligibility","conceptCode":"C40412","definition":"The state or quality of being disqualified by law, rule, or provision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B262-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87362511-B27D-24FC-E053-F662850A59E3","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"},{"value":"Cisplatin Resistant","valueDescription":"Cisplatin Resistance","ValueMeaning":{"publicId":"6712213","version":"1","preferredName":"Cisplatin Resistance","longName":"6712213","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.: Failure of a cancer to shrink after treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Resistance","conceptCode":"C19391","definition":"Failure of a cancer to shrink after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B28A-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87362511-B2A5-24FC-E053-F662850A59E3","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87362511-B247-24FC-E053-F662850A59E3","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-04-23","changeDescription":"Curated to support EC10183","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior Cisplatin Exposure","type":"Preferred Question Text","description":"Prior Cisplatin Exposure","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87384F0A-F7C1-24B1-E053-F662850AEAAC","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-23","modifiedBy":"HARTLEYG","dateModified":"2019-04-23","changeDescription":"Curated to support EC10183","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}